New Frequency Therapeutics Study Confirms Drug Delivery to the Inner Ear
WOBURN, MASSACHUSETTS — Frequency Therapeutics, Inc., announced top-line data from an exploratory clinical study designed to show whether drug levels of FX-322 in the cochlea can be directly measured. In addition to confirming the viability of the approach, study results showed measurable concentrations of FX-322 in every patient and that anatomical factors did not prevent…
Read MoreFrequency Therapeutics Provides Business Updates and Reports Q3 2019 Financial Results
WOBURN, MASSACHUSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced business updates and financial results for the third quarter ending September 30, 2019. “This has been a tremendously productive period for…
Read MoreFDA Grants FX-322 Fast Track Designation, for Treatment of Sensorineural Hearing Loss
WOBURN, MASSACHUSETTS — Biotech startup Frequency Therapeutics today announced that dosing has commenced in a Phase 2a clinical study of FX-322, a locally administered investigational drug candidate designed to regenerate auditory hair cells and restore hearing function. The objectives of the Phase 2a study are to further establish the positive hearing signal observed in Frequency’s…
Read More
Frequency Therapeutics Goes Public; Company Debuts IPO at $84M
WOBURN, MASSACHUSSETTS — Biotech startup Frequency Therapeutics announced the pricing of its initial public offering (IPO) at approximately $84 million. The company is planning to use funds raised by the IPO to complete the Phase 2a trial of FX-322, a regenerative therapeutic for the treatment of sensorineural hearing loss and also to advance discovery programs…
Read More
Frequency Therapeutics Eyes $100 Million IPO to Further Develop Hearing Loss Drug, FX-322
WOBURN, MASSACHUSSETTS — Biotech startup Frequency Therapeutics has set a preliminary $100 million IPO target, according to paperwork filed with the US Securities Exchange Commission (SEC) on Friday. The company has applied for a Nasdaq listing under the stock symbol ‘FREQ’. Frequency plans to use the money raised by the IPO to complete the Phase…
Read More
Frequency Therapeutics Raises $62 Million in Latest Financing Round to Support Hearing Loss Drug Development
WOBURN, MASSACHUSSETTS — Frequency Therapeutics, a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the closing of a $62.0 million Series C financing. Frequency will use the proceeds to support the clinical development of FX-322, a regenerative therapeutic…
Read More
Astellas and Frequency Therapeutics Reach License Agreement for FX-322
TOKYO, JAPAN and WOBURN, MASSACHUSETTS — Astellas Pharma and Frequency Therapeutics today announced that they have entered into an exclusive license agreement to develop and commercialize Frequency’s regenerative therapeutic candidate, FX-322, for the treatment of sensorineural hearing loss, the most common type of hearing loss. Under the terms of the agreement, Astellas will be responsible…
Read MoreFrequency Therapeutics Announces Positive Phase 1/2 Trial Results for Hearing Restoration Drug
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an investigational drug candidate designed to facilitate hearing restoration. The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who had a medical…
Read More
Frequency Therapeutics Completes $42 Million Series B Financing
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced earlier this month that it has closed $42 million in Series B financing. The latest funding round for the company, which is seeking to create a new class of drugs based on small molecule stimulation of dormant stem cells within the body, brings the total capital raised…
Read MoreFrequency Therapeutics Completes Enrollment in Safety Trial for Hearing Restoration Drug Candidate, FX-322
WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced this week the completion of enrollment in the single dose safety trial to evaluate FX-322, the company’s leading drug candidate for hearing restoration. The randomized, double-blind, placebo-controlled trial will be assessing the safety of a single dose of FX-322 given by intratympanic administration in adult patients with…
Read More